Transgenomic, Inc., a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, announced that its shares of common stock have been approved for uplisting to the NASDAQ Capital Market.
Effective Friday, May 9, the stock will trade on NASDAQ under the symbol TBIO, the Company noted in a release.
"Uplisting to Nasdaq represents a key milestone for Transgenomic as we continue our transition into a leading player in the rapidly growing field of personalized medicine," said Paul Kinnon, President and Chief Executive Officer of Transgenomic. "Uplisting to a national exchange was an important goal for the company. We believe that trading on the NASDAQ market will expand our visibility and provide us access to a broader investor base, helping us translate our strategic growth initiatives and renewed focus on implementation into increased shareholder value going forward."
Transgenomic develops and commercializes diagnostic assays and testing kits with the goal of improving medical diagnoses and patient outcomes.
Transgenomic said that its common shares will continue to trade on the OTC Bulletin Board under its existing ticker symbol "TBIO" until the market closes on Thursday, May 8.
((Comments on this story may be sent to firstname.lastname@example.org))